Salbutamol
- Generic Name
- Salbutamol
- Brand Names
- Airomir, Airsupra, Combivent, Proair, Proventil, Ventolin
- Drug Type
- Small Molecule
- Chemical Formula
- C13H21NO3
- CAS Number
- 18559-94-9
- Unique Ingredient Identifier
- QF8SVZ843E
- Background
Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart. Salbutamol is formulated as a racemic mixture of the R- and...
- Indication
Salbutamol is indicated for (i) the symptomatic relief and prevention of bronchospasm due to bronchial asthma, chronic bronchitis, reversible obstructive airway disease, and other chronic bronchopulmonary disorders in which bronchospasm is a complicating factor, and/or (ii) the acute prophylaxis against exercise-induced bronchospasm and other stimuli known t...
- Associated Conditions
- Asthma, Asthmatic Bronchitis, Bronchial Asthma, Bronchoconstriction, Bronchospasm, Chronic Asthma, Chronic Bronchitis, Cough, Emphysema, Exacerbation of asthma, Exercise-Induced Bronchospasm, Hyperkalemia, Wheezing, Excess mucus or phlegm
- Associated Therapies
- Airway secretion clearance therapy, Bronchodilation
Study Investigating Repeat Doses Of A New Medication (GSK159797) In Asthmatic Patients
- Conditions
- Interventions
- First Posted Date
- 2006-07-31
- Last Posted Date
- 2016-10-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 54
- Registration Number
- NCT00358488
- Locations
- 🇬🇧
GSK Investigational Site, Manchester, United Kingdom
Bronchodilators and Oxygen Kinetics With Exercise in Chronic Obstructive Pulmonary Disease (COPD) Patients
- First Posted Date
- 2006-07-20
- Last Posted Date
- 2011-04-19
- Lead Sponsor
- Queen's University
- Target Recruit Count
- 12
- Registration Number
- NCT00354354
- Locations
- 🇨🇦
Respiratory Investigation Unit (Queen's University), Kingston, Ontario, Canada
Viapaed Study In Children And Adolescents With Asthma
- Conditions
- Interventions
- First Posted Date
- 2006-04-19
- Last Posted Date
- 2017-10-19
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 285
- Registration Number
- NCT00315744
- Locations
- 🇩🇪
GSK Investigational Site, Hamburg, Germany
The Effect of Nebulized Albuterol on Donor Oxygenation
- Conditions
- Interventions
- First Posted Date
- 2006-04-03
- Last Posted Date
- 2018-03-16
- Lead Sponsor
- Vanderbilt University Medical Center
- Target Recruit Count
- 506
- Registration Number
- NCT00310401
- Locations
- 🇺🇸
California Transplant Donor Network, Oakland, California, United States
Chronic-Dose Safety and Efficacy Study of Albuterol-HFA-BAI in Pediatric Asthmatics
- First Posted Date
- 2006-03-30
- Last Posted Date
- 2022-04-01
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 95
- Registration Number
- NCT00308685
- Locations
- 🇺🇸
Allergy & Asthma Specialist Medical Group, Huntington Beach, California, United States
🇺🇸Little Rock Allergy and Asthma, Little Rock, Arkansas, United States
🇺🇸Allergy & Asthma Associates of Santa Clara Valley Research Center, San Jose, California, United States
Effect of Budesonide / Formoterol Combination in Repeated AMP Provocations
- Conditions
- First Posted Date
- 2006-01-09
- Last Posted Date
- 2011-06-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 20
- Registration Number
- NCT00272753
- Locations
- 🇳🇱
Research Site, Groningen, Netherlands
Genetic Determinants of the Response to Salbutamol Among Asthma Patients
- Conditions
- First Posted Date
- 2005-09-13
- Last Posted Date
- 2008-10-29
- Lead Sponsor
- Hadassah Medical Organization
- Target Recruit Count
- 150
- Registration Number
- NCT00162396
- Locations
- 🇮🇱
Hadassah Medical Organization, Jerusalem, Israel
Genetic Determinants of the Bronchodilatation Effect of Albuterol ex-Vivo
- Conditions
- First Posted Date
- 2005-09-13
- Last Posted Date
- 2008-10-29
- Lead Sponsor
- Hadassah Medical Organization
- Target Recruit Count
- 150
- Registration Number
- NCT00162422
- Locations
- 🇮🇱
Hadassah Medical Organization, Jerusalem, Israel
Treatment of Multiple Sclerosis With Copaxone and Albuterol
- Conditions
- Interventions
- First Posted Date
- 2002-06-20
- Last Posted Date
- 2016-09-22
- Target Recruit Count
- 40
- Registration Number
- NCT00039988
- Locations
- 🇺🇸
Brigham and Women's Hospital/Harvard Medical School, Boston, Massachusetts, United States
Study of Albuterol and Oxandrolone in Patients With Facioscapulohumeral Dystrophy (FSHD)
- Conditions
- First Posted Date
- 2001-12-07
- Last Posted Date
- 2015-03-25
- Lead Sponsor
- FDA Office of Orphan Products Development
- Target Recruit Count
- 160
- Registration Number
- NCT00027391
- Locations
- 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.